Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung cancer
- Conditions
- on-squamous Non-small-cell Lung Cancer
- Registration Number
- JPRN-UMIN000003566
- Lead Sponsor
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
- Brief Summary
The overall response rate was 76%. The median progression free survival and overall survival were 8.4 months and 22.2 months, respectively. Grade 3-4 toxicities included neutropenia in 55% of patients, anemia in 18%, febrile neutropenia in 12%, and anorexia in 9%. No treatment-related deaths were observed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 33
Not provided
(1) brain metastasis (2) active concomitant malignancy (3) Current or previous history of hemoptysis or active hemosputum (4) evidence of bleeding diathesis or coagulopathy (5) Current or previous history of Pericardial effusion (6) superior vena cava syndrome (7) spinal cord compression (8) Current or previous (within the last 1 year) history of cerebrovascular disease (9) Traumatic fracture of unrecovery (10) History of active infection (11) The operation has been scheduled for the examination period (12) receiving anticoagulant drug(except Aspirin under 324mg/day) (13) Uncontrollable Gastrointestinal ulceration (14) Current or previous (within the last 1 year) history of GI perforation (15) Uncontrollable hypertension (16) severe cardiac disease (17)Interstitial pneumonia or pulmonary fibrosis detectable on CT scan or X-ray (18)peripheral neuropathy > Grade2 (19) severe drug allergy (20) history of hypersensitivity of Taxans or alcohol and the medicine made of the polio castor oil content (21) treatment history of bevacizumab (22) History of pregnancy or lactation (23) No intention to practice birth control (24) those judged to be not suitable by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Safety, Progression free survival, Time to response, Response duration, Overall survival